Glenmark Has An Orphan Ahead of Innovation Capital Raising Plan

 
• By Anju Ghangurde

FDA orphan drug designation for Glenmark’s multiple myeloma candidate is seen as an important milestone ahead of its innovation spin out’s plans to raise capital in the US to fund pipeline development.

Hands holding rope forming arrow pointing upwards - Image
US Orphan Designation For Glenmark Clinical Asset • Source: Shutterstock

More from R&D

More from Scrip